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We previously identified a decapeptide from the model plant Arabidopsis thaliana, OSIP108, which is induced upon fungal
pathogen infection. In this study, we demonstrated that OSIP108 interferes with biofilm formation of the fungal pathogen Can-
dida albicans without affecting the viability or growth of C. albicans cells. OSIP108 displayed no cytotoxicity against various
human cell lines. Furthermore, OSIP108 enhanced the activity of the antifungal agents amphotericin B and caspofungin in vitro
and in vivo in a Caenorhabditis elegans-C. albicans biofilm infection model. These data point to the potential use of OSIP108 in
combination therapy with conventional antifungal agents. In a first attempt to unravel its mode of action, we screened a library
of 137 homozygous C. albicansmutants, affected in genes encoding cell wall proteins or transcription factors important for bio-
film formation, for altered OSIP108 sensitivity. We identified 9 OSIP108-tolerant C. albicansmutants that were defective in ei-
ther components important for cell wall integrity or the yeast-to-hypha transition. In line with these findings, we demonstrated
that OSIP108 activates the C. albicans cell wall integrity pathway and that its antibiofilm activity can be blocked by compounds
inhibiting the yeast-to-hypha transition. Furthermore, we found that OSIP108 is predominantly localized at the C. albicans cell
surface. These data point to interference of OSIP108 with cell wall-related processes of C. albicans, resulting in impaired biofilm
formation.
Yeasts of the genus Candida are opportunistic human fungalpathogens causing life-threatening systemic infections, par-
ticularly in immunocompromised patients. Candida spp. are rec-
ognized as the fourth most common cause of bloodstream infec-
tions in the United States (1), with high attributable mortality
rates up to 40% (2). Although Candida glabrata and Candida kru-
sei are increasingly being isolated and have an increased resistance
to commonly used antifungals,Candida albicans remains the most
common fungal pathogen (3–5). In natural environments like the
human body,Candida spp. occur preferably in biofilms. The latter
are well-structured populations of microbial cells attached to a
surface and embedded in a self-produced polymer matrix (6, 7).
Biofilms have a great significance for public health, as they are
critical in the development of clinical infections and are frequently
refractory to conventional antimicrobial agents (8, 9). From the
currently available antifungal agents, liposomal formulations of
amphotericin B (AMB) and the echinocandins such as caspofun-
gin (CAS) can effectively treat C. albicans biofilms (10). As those
two classes of antifungal agents have limitations due to toxicity,
resistance, and bioavailability issues, we are clearly in need of
new antibiofilm agents and therapies. In combination with im-
proved assays for faster and more sensitive diagnosis of biofilm
involvement in fungal infections (11), another need in current
antimycotic therapies, such novel antibiofilm compounds
would significantly improve the efficacy of current treatments
of biofilm-associated fungal infections.
Candida species often form biofilms on medical devices, such
as urinary and vascular catheters, (dental) implants, prostheses,
and heart valves (12, 13). Besides their role as a constant source of
cells leading to chronic infections due to their increased resistance
to antifungal treatment, those biofilms may also cause device fail-
ure. Treatment often requires the removal of the device, which is
associated with high costs and patient discomfort (13). Besides
systemic administration of antibiofilm molecules to cure biofilm-
associated infections, such molecules can be used as a coating on
medical devices, thereby preventing proper biofilm formation of
microbial pathogens on the device and thus resulting in a reduced
risk for the development of biofilm-associated device infections.
Current antibiofilm coatings of medical devices are mainly based
on the use of silver ions, which are toxic upon accumulation (14),
or on the release of standard antibiotics/antimycotics for which
biofilms display increased resistance.
The study of plants as an alternative to other forms of drug
discovery has attracted great attention because, according to the
World Health Organization, these would be the best sources for
obtaining a wide variety of drugs and could benefit a large popu-
lation (15). We previously identified a decapeptide of Arabidopsis
thaliana, OSIP108, which is induced in plants upon infection by
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the fungal pathogen Botrytis cinerea (16). In this study, we inves-
tigated the potential antifungal effect of OSIP108 against different
fungi, including the human pathogenC. albicans. Furthermore, as
microbial biofilm formation was recently found to be a prerequi-
site for infection in various hosts, we also investigated the effect of
OSIP108 on biofilm formation of C. albicans. We subsequently
performed a preliminary structure-activity relationship study of
OSIP108 consisting of a scrambled version and cyclic derivatives
of OSIP108 and investigated possible cytotoxic effects of OSIP108
against human osteoblasts, mesenchymal stem cells, and endothe-
lial cells. In addition, we investigated the effects of OSIP108 on the
activities of commonly used antifungal agents such as AMB and
CAS against mature biofilms in vitro and in vivo in a Caenorhab-
ditis elegans-C. albicans infection model. Finally, to gain more in-
sight into the antibiofilm activity of OSIP108, we screened a li-
brary of 137 C. albicans homozygous mutants affected in cell wall
proteins or transcription factors for both resistance and hypersen-
sitivity to OSIP108, aiming at identification of OSIP108 targets
and tolerance mechanisms to OSIP108 inC. albicans, respectively.
MATERIALS AND METHODS
Strains and chemicals. The strains C. albicans SC5314, CAI4, CAF2 (17),
DAY286 (18), B2630, and B63195 (19); C. glabrata BG2 (20); Candida
dubliniensis NCPF 3949 (21); and C. krusei IHEM 6104 (Belgian Coordi-
nated Collections Of Microorganisms [BCCM]/IHEM, Brussels, Bel-
gium) were used in this study. Homozygous deletion mutants derived
from C. albicans BWP17 (22) with the isogenic wild-type (WT) strain
DAY286 were ordered from the Fungal Genetics Stock Center (FGSC)
(23) (University of Missouri, Kansas City, MO) and sent by M. L. Richard
(24). The following homozygous deletion mutants of (i) cell wall proteins
(pga62, pde2, hoc1, orf19.10953, gal10, ecm17, rot11, mpt5,
orf19.12732, orf19.1277, iff11, wsc2, mnn4, pga7, mnn10,
hwp1, rbt1, snf7, cis2, Fig1, nup, eap1, ecm29, irs4, msb2,
spr3, ecm3, pga44, mp65, cyc3, ccw14, dfg5, vsp28, spr1,
orf19.2296, orf.19.2332, orf19.2336, sap8, orf19.2476, orf19.251,
ecm4, ahp1, pga62, ecm14, orf19.2996, ecm33, bmh1, pra1,
dot4, hwp2, orf19.3434, sun41, rax2, sap10, orf19.3869, cht2,
crh12, adh1, ecm331, bni4, ktr4, csh1, als9, bgl2, pga6,
ecm21, ecm25, hyr1, orf19.4981, pga21, orf19.5401, orf19.5412,
cdc10,phr3,rbt5,pga10,wsc1,cmp1,atc1,sdh2,plb2,ssr1,
csa1, rbe1, wsc4, bgl22, kre6, mnn9, iff4, lrg1, cda2, cht1,
cht3,chs5,sap98,kre62,pga17,pga55,pga33,pga17,pga40,
pga50, pga27, pga3 [sod5], pga2 [sod4], pga9 [sod6], pga45,
pga42, pga43, mid1, pga8 [hwp2], ywp1, pga5, pga23, pga37,
pga4, pga57, pga6, pga30, pga36, pga39, pga32, sap9, and
pga31) and (ii) transcription factors involved in hyphal morphogenesis
(rim101, cph1, tec1, czf1, cph2, tup1, and rfg1) were tested.
Candida strains were grown routinely on yeast-peptone-dextrose (YPD)
(1% yeast extract, 2% peptone, and 2% glucose) agar plates at 30°C for 2
days. RPMI 1640 medium (pH 7.0) with L-glutamine and without sodium
bicarbonate was purchased from Sigma and buffered with MOPS (mor-
pholinepropanesulfonic acid) (Sigma, St. Louis, MO, USA). Amphoteri-
cin B (AMB), cholesterol, ampicillin, and kanamycin were purchased
from Sigma (St. Louis, MO, USA). Caspofungin (CAS) (Cancidas) was
purchased from Merck (Beeston Nottingham, United Kingdom). The
plant defensin RsAFP2 was isolated from radish seeds (Raphanus sativus)
as described previously (25).
Peptide synthesis. The following peptides (and corresponding sequences)
were used: OSIP108 (MLCVLQGLRE), S-OSIP108 (scrambled-OSIP108 with
sequence ELRLVCMGQL), D-OSIP108 (MLCVLQGLRE [all D-amino acids]),
[CYC1]OSIP108 (head-to-tail cyclized-MLCVLQGLRE), [CYC2]OSIP108
(head-to-tail cyclized-MLCVLQGLREGG), and [CYC3]OSIP108 (disulfide
cyclized-MLCVLQGLREC [C3 to C11 cyclization]). OSIP108, S-OSIP108, D-
OSIP108, and [Cyc3]OSIP108 (MLCVLQLGREC) were synthesized via Fmoc-
protectedsolid-phasepeptidechemistryusingstandardmethods(26).Briefly,the
peptideswereassembledona2-chlorotritylchlorideresin(100to200mesh)from
Peptide International (Louisville, KY) and cleaved off the resin after complete
chain assembly with trifluoroacetic acid (TFA)/triisopropylsilane/water (96:2:2)
for 2.5 h. [Cyc3]OSIP108 was oxidized in a folding buffer made of acetic acid/
dimethyl sulfoxide (DMSO)/water (5:10:85) at room temperature for 48 h at a
final peptide concentration of 0.25 mg/ml. The other two cyclic OSIP108 pep-
tides, [Cyc1]OSIP108 (cyclo-MLCVLQGLRE) and [Cyc2]OSIP108 (cyclo-
MLCVLQGLREGG), were synthesized using Boc-protected solid-phase peptide
chemistry, with thioester-mediated native chemical ligation to achieve the head-
to-tail cyclization (27). Briefly, peptides were assembled on a Boc-Gly-PAM resin
(100 to 200 mesh) from Peptide International (Louisville, KY). After coupling of
thethioester linkerandcompleteassemblyof thepeptidechain, the linearpeptide
precursors were cleaved off the resin. The head-to-tail cyclization was carried out
using native chemical ligation in 0.1 M ammonium bicarbonate buffer (pH 8.3),
containing 2 mM Tris(2-carboxyethyl)phosphine (TCEP), overnight at room
temperature with a final peptide concentration of 0.25 mg/ml.
Liquid chromatography and mass spectrometry. All OSIP108 ana-
logues were purified using a Shimadzu Prominence high-pressure liquid
chromatography (HPLC) system (Shimadzu Corp., Kyoto, Japan), in-
cluding an LC-20AT pump and SPD-20A UV-visible light (UV-VIS) de-
tector, and using a reversed-phase Jupiter C18, 250- by 21.20-mm, 5-m
column (Phenomenex, Inc., Torrance, CA). Final purity of the com-
pounds was checked on a liquid chromatography-mass spectrometry
(LC-MS) Shimadzu Prominence system equipped with double LC-20AD
micropumps, an SPD-20A UV/VIS detector, and a Shimadzu electrospray
ionization (ESI)-MS 2020 mass spectrometer. Peptides were injected onto
a Jupiter C18, 150- by 2.00-mm, 5-m (Phenomenex, Inc.) column. After
5 min in isocratic 1% solvent B, a gradient of 2% per minute from 1 to 81%
was applied before washing and equilibrating the column back to 1% B
(solvent A, 0.05% formic acid [FA] in H2O, and solvent B, 0.045% FA,
10% H2O, and 90% acetonitrile [AcN]). All synthetic peptides were of
high purity (97%) and had the correct mass (see Fig. S1 and Table S1 in
the supplemental material).
Circular dichroism. Circular dichroism (CD) spectroscopy is com-
monly used to evaluate peptide secondary structure (28) and is also useful
to confirm enantiomeric relationships (29). Thus it was used here to con-
firm the mirror-image nature of the D- and L-OSIP108 isomers. Briefly,
each individual enantiomer and a 50:50 mixture of both were prepared at
a concentration of 50M in water. A 0.1-cm path-length cuvette was filled
with the desired solution and placed into a Jasco J-810 CD spectropola-
rimeter. The spectrum was recorded from 185 to 260 nm at a speed of 50
nm per minute. The solvent signal was subtracted and the CD spectrum
transformed to mean residue molar ellipticity []MR.
MIC assay. The MIC-2, which is the minimum concentration that
reduces growth by 50% compared to the growth control, was deter-
mined according to the CLSI M27-A3 protocol for antifungal suscep-
tibility testing of yeasts in RPMI 1640 medium with a 1% DMSO
background (30). The concentration range used for the OSIP108 pep-
tide was 0.39 to 200 M.
Antibiofilm assay. The inhibitory potential of OSIP108 and its ana-
logues on Candida biofilm formation was assessed using the CellTiter
Blue (CTB) quantification method (31) or the 2,3-bis(2-methoxy-4-ni-
tro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydrox-
ide (XTT) assay (32). To this end, an overnight culture ofCandida in YPD
was washed with phosphate-buffered saline (PBS) and a cell suspension of
106 cells/ml was prepared in RPMI 1640 medium (pH 7.0). Two-fold
dilution series of the peptides (dissolved in 100% DMSO) were prepared
in RPMI 1640. Five-microliter volumes of these series were added with 95
l of inoculum to each well of a round-bottomed polystyrene 96-well
microtiter plate (TPP; Trasadingen, Switzerland), resulting in a back-
ground of 0.5% DMSO. After 24 h of incubation, biofilms were washed
and quantified with CTB as described previously (33). Activities of
OSIP108 against biofilms ofC. glabrata,C. dubliniensis, andC. kruseiwere
assessed with the XTT assay as described previously (33), since those Can-
Delattin et al.
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dida spp. did not convert CTB within 1 h. The activity of OSIP108 and its
derivatives against Candida biofilm formation is expressed as the biofilm-
inhibiting concentration 2 (BIC-2), which is the minimum concentration
of the peptides that reduces biofilm formation by 50% compared to the
growth control. RPMI 1640 medium for OSIP108 antibiofilm tests against
C. albicansCAI4 was supplemented with 50g/ml uridine (URA) as CAI4
is URA deficient.
To determine activities of OSIP108 against mature biofilms of C. albi-
cans, we used a slightly adapted protocol. One hundred microliters of the
above-described cell suspension (106 cells/ml in RPMI 1640) was added to
the wells of a round-bottomed polystyrene 96-well microtiter plate, and
after 1 h of adhesion at 37°C, wells were washed with PBS. Subsequently,
100 l fresh RPMI 1640 medium was added to each well. Upon 24 h of
incubation, biofilms were washed with PBS, and 2-fold dilution series of
OSIP108 prepared in RPMI 1640 were added to the biofilms (0.5% DMSO
background). After 24 h of treatment, biofilms were washed with PBS and
quantified with CTB. Antibiofilm activity of OSIP108 against mature C.
albicans biofilms is expressed as the biofilm-eradicating concentration 2
(BEC-2), which is the minimum concentration that eradicates 50% of the
biofilm cells compared to the growth control.
Assessment of cytotoxicity. Cell viability of three human primary cell
cultures, namely, osteoblasts, mesenchymal stromal cells, and microvas-
cular endothelial cells, was tested with trypan blue staining according to
the ISO 10993-5 standard. Briefly, cells were seeded at 2 104 cells/cm2 to
96-well plates, and then were exposed in four replicates to (i) medium for
osteoblasts and mesenchymal stromal cells (advanced Dulbecco modified
Eagle medium [DMEM], 10% fetal bovine serum [FBS], 1 GlutaMAX,
and 0.05 mg/ml gentamicin) or for microvascular endothelial cells (me-
dium 131 with microvascular growth supplement and 0.05 mg/ml genta-
micin [all from Gibco, Carlsbad, CA] with 0.5% DMSO background), (ii)
medium with 0.05% phenol (cytotoxic control), and (iii) medium with
OSIP108 (12.5 M). After 6 days of culture, the cell culture medium was
removed from 96 wells and one-third of trypan blue in DMEM medium
was added to the culture for 3 min. Dead (blue) and live (transparent) cells
in two visual fields were counted in each of the four wells.
Tube formation assay. Human aortic endothelial cells were cultured
in M200 medium with low serum growth supplement (all from Gibco,
Carlsbad, CA). For the tube formation assay, the surface of a 24-well plate
was coated with 250 l of phenol-red free Matrigel (Becton, Dickinson,
Bedford, MA) per well and cells were seeded at 2  104 cells/cm2. The
medium was supplemented with DMSO (0.5%) and phenol (0.05%) or
OSIP108 (12.5 M). Eight hours after seeding of the cells, three random
phase-contrast digital images in each of the three wells per treatment were
taken with a digital camera (DS-Fi1; Nikon, Tokyo, Japan) using a 10
objective lens. Tube-like structures were analyzed with ImageJ software
(http://rsbweb.nih.gov/ij/), and the average tube length per field was cal-
culated.
Osteogenic differentiation. To test the effect of OSIP108 on osteo-
genic differentiation potential, osteoblasts and mesenchymal stromal cells
were cultured in following culture media: (i) osteogenic medium (osteo-
genic differentiation Bulletkit [Lonza, Basel, Switzerland] and 0.05 mg/ml
gentamicin) with 0.5% DMSO background and (ii) osteogenic medium
with 12.5 M OSIP108. Osteoblast and mesenchymal stromal cell cul-
tures were harvested after 3 or 5 weeks for the calcium and DNA assay.
Calcium andDNA assay. Calcium deposition of osteoblasts and mes-
enchymal stromal cells was measured with the Stanbio calcium CPC
LiquiColor test (Stanbio Laboratory, Boerne, TX). Briefly, cell cultures
were extracted by 5% trichloroacetic acid (500 l per sample). o-Cresol-
phthalein complex was added, and the calcium content was determined
spectrophotometrically at 550 nm.
To determine the DNA content, cells were washed with PBS, and 200
l of digestion buffer (10 mM Tris, 1 mM EDTA, 0.1% Triton X-100, and
0.1 mg/ml proteinase K) was added. Samples were incubated in digestion
buffer overnight at 56°C. The supernatants were drawn off, and Pi-
coGreen dye (Molecular Probes, Eugene, OR) was added to the superna-
tants in a 1:1 ratio and read in a fluorescent plate reader (excitation 485
nm and emission 528 nm). DNA values were used to normalize calcium
content. Four wells per condition were examined, and two samples from
each well were taken for each assay.
Statistical analysis. Statistical significance of the results from the
above-described cell assays was tested with one-way ANOVA followed by
Tukey’s test. Differences were considered statistically significant at P val-
ues of0.05.
Checkerboard antibiofilm assay. To determine synergistic interac-
tions between OSIP108 and the antifungals AMB or CAS against C. albi-
cans biofilms, checkerboard analysis was used and fractional inhibitory
concentration index (FICI) values were calculated. The FICI was calcu-
lated by the formula FICI [C(BEC-2A)/BEC-2A]	 [C(BEC-2B)/BEC-
2B], in which C(BEC-2A) and C(BEC-2B) are the BEC-2s of the antifun-
gal drugs in combination, and BEC-2A and BEC-2B are the BEC-2s of
antifungal drugs A and B alone. The interaction was defined as synergistic
if the FICI was0.5, indifferent if it was between 0.5 and 4, and antago-
nistic if it was 4.0 (34). Biofilms were grown to maturity as described
above. After 24 h of biofilm formation at 37°C, biofilms were washed with
100l PBS, after which 100l of a combination of OSIP108 (3.125 to 100
M) with AmB or CAS (0.01 to 5 M), 2-fold diluted in RPMI 1640
medium across columns and rows of the microtiter plate, respectively, was
added to each well (final DMSO background 0.6%). After 24 h of treat-
ment at 37°C, metabolic activity was quantified with the CTB method as
described previously (33). The FICI value for the OSIP108-AMB and
OSIP108-CAS interactions of 3 independent experiments is shown.
Worm infection assay. In vivo experiments using the C. elegans-C.
albicans biofilm infection model were performed as described previously
(33). The glp4/sek1 deletion strain of C. elegans was used to avoid the
production of progeny, which is undesirable in this assay as (i) it makes it
difficult to score the viability of the infected parents and (ii) Candida-
infected wild-type nematodes exhibit significant matricidal death (over
30%) (35). To investigate potential synergy between OSIP108 and CAS in
vivo, worms, infected with C. albicans, were treated with 100 M
OSIP108, 0.095 M CAS, and 100 M OSIP108 plus 0.095 M CAS or
0.6% DMSO (negative control). We used this specific concentration of
CAS as it has only a modest effect on the survival of the infectedC. elegans,
namely, 20% of the worms survived after 7 days. As a control, the survival
of noninfected worms was also monitored. Worm survival was expressed
as a percentage of their viability at day zero. Data shown represent the
mean and standard error of the mean of a representative experiment out
of 3 independent experiments with at least 3 replicates/condition. Results
were analyzed for statistical significance by unpaired Student’s t test. Val-
ues were considered to be statistically significant when the P value was
0.05.
Screening of homozygous deletion mutants. Homozygous C. albi-
cans cell wall protein deletion mutants (n 130) and homozygous dele-
tion mutants of transcription factors (n 7) involved in hyphal morpho-
genesis derived from C. albicans BWP17 with isogenic WT DAY286 were
screened for their ability to form biofilms in the presence of OSIP108.
Biofilms were grown and treated as mentioned above in the presence of 25
M or 6.25 M OSIP108 or 0.5% DMSO (control) for 24 h at 37°C.
Biofilm formation was quantified with the CTB assay, and a sensitivity
factor (SF) was calculated as SF average % fluorescence mutant at 25 or
6.25 M OSIP108 relative to control treatment mutant (0.5% DMSO)/
average % fluorescence WT DAY286 at 25 or 6.25M OSIP108 relative to
control treatment WT (0.5% DMSO). Subsequently, resistant or hyper-
sensitive mutants were selected (SF,2 or0.5) for further susceptibility
testing toward OSIP108 in a broader concentration range (0.78 to 100
M) to determine the antibiofilm effect of OSIP108 against the selected
mutants compared to the isogenic WT DAY286.
FITC-OSIP108 localization study. Cellular localization of OSIP108
was investigated using an N-terminal-labeled fluorescein isothiocyanate
(FITC)-OSIP108 (FITC-MLCVLQGLRE; ChinaPeptides, Shanghai, China).
C. albicans biofilms were grown in the presence of 50 M FITC-OSIP108
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as described above. FITC labeling of the peptide did not affect antibiofilm
activity. Biofilm cells were collected and washed 3 times with PBS and
visualized using a Zeiss Axio Imager Z1 fluorescence microscope using the
FITC channel (excitation wavelength, 450 to 490 nm; emission wave-
length, 500 to 550 nm; exposure time, 1.41 s).
Mkc1p phosphorylation assay. A single colony of WT SC5314 C.
albicans was inoculated into 10 ml YPD and grown 8 h at 30°C. Cells were
diluted 1:125 into 50 ml RPMI 1640 and grown with shaking at 25°C
overnight. Cells were treated with OSIP108 (100M) or DMSO (0.5%) as
the control treatment for 1 h. Cells were collected over ice, and total
protein was extracted as described previously (36). A total of 60g (phos-
pho-Mkc1p) or 20 g (actin) total protein was loaded per sample on an
8.5% (phospho-Mkc1p) or 10% (actin) SDS-PAGE gel. Gels were trans-
ferred onto 0.2-m polyvinylidene difluoride (PVDF) membranes using
standard protocols and probed with anti-dually phosphorylated p42/44
mitogen-activated protein kinase (MAPK) rabbit monoclonal antibody
(CS-4380; Cell Signaling) or with rabbit anti-actin (A5060; Sigma).
Horseradish peroxidase (HRP)-conjugated goat anti-rabbit (Invitrogen)
was used as a secondary antibody, and signal was detected using Pierce
ECL Western-blotting substrate (Thermo Scientific number 32209) as
directed. The signal was visualized and quantified with a Syngene GBox
Chemi imager and GeneSys software. The experiment was repeated three
times, and a representative blot is shown.
Yeast-to-hypha transition assay using solid-phase cytometry. To
determine the effect of OSIP108 on the yeast-to-hypha transition of C.
albicans, the fraction of hyphae was determined using solid-phase cytom-
etry as described previously (37). Biofilms were grown as described above
in the presence of OSIP108 (12.5 and 50 M), S-OSIP108 (12.5 and 50
M), and the DMSO control (0.5%). As the active OSIP108 concentra-
tions used allow only the formation of loosely attached biofilms, the total
percentage of hyphal mass was determined per well after 24 h of biofilm
formation without washing. Biofilms were detached by sonication for 10
min and thorough pipetting up and down. Biofilm cells were diluted 1,000
times in particle-free 0.9% (wt/vol) NaCl, and further processing of the
diluted suspensions and analysis of the fluorescent signals was performed
as previously described (37).
RESULTS AND DISCUSSION
OSIP108 interferes with C. albicans biofilm formation without
affecting yeast viability. We assessed the effect of OSIP108 on
planktonic C. albicans cells and on the biofilm formation process
of this pathogen. OSIP108 displayed no antifungal activity against
C. albicans (MIC-2,200M), and the addition of up to 200M
OSIP108 to C. albicans cells did not affect their viability after 24 h
of incubation. In contrast, OSIP108 strongly reduced C. albicans
biofilm formation when added during the adhesion and biofilm
formation phases. Biofilms formed in the presence of OSIP108
(6.25 to 100 M) were very easily detached, pointing to a strong
interference of OSIP108 with the C. albicans biofilm structure.
The BIC-2 of OSIP108 was 5.3 M (Fig. 1; Table 1). However,
OSIP108 did not eradicate 24-h-old C. albicans biofilms, as the
BEC-2 of OSIP108 was 800 M. In order to compare the anti-
biofilm potential of OSIP108 with that of conventional antifungal
agents, we also determined the antibiofilm activity of amphoteri-
cin B (AMB) and caspofungin (CAS) in our setup. The BIC-2
values of AMB and CAS were 0.4 and 0.06M, respectively, while
the BEC-2 values were 0.72 and 0.52 M, respectively. It is clear
that the antibiofilm activity of OSIP108 is lower than that of the
conventional antifungal agents. However, in contrast to these an-
tifungal agents, OSIP108 has no fungicidal or antifungal activity,
which is beneficial in terms of the development of resistance. Next,
we tested OSIP108’s ability to inhibit biofilm formation against
other C. albicans strains and Candida spp. (Table 1). C. albicans
strains CAI4, CAF2, and DAY286 are laboratory strains derived
from SC5314 (17). C. albicans B2630 and B63195 are azole-sensi-
tive strains (19). OSIP108 displayed antibiofilm activity against all
C. albicans strains tested (BIC-2, 4.5 to 10.8M) (Table 2) but not
against other pathogenic Candida spp., such as C. glabrata, C.
dubliniensis, andC. krusei (BIC-2,100M) (Table 1). Together,
these data demonstrate that the activity of OSIP108 is biofilm
specific, as OSIP108 displayed no antifungal/fungicidal activity,
but was restricted to interference with the biofilm formation of C.
albicans strains. Though the lack of activity against other Candida
spp. is not favorable for the development of OSIP108 as a broad-
FIG 1 OSIP108 antibiofilm activity with and without the yeast-to-hypha in-
hibitor RsAFP2. C. albicans SC5314 biofilms were grown in the presence of
OSIP108 alone (0.78 to 100 M; dotted line) or in the presence of the plant
defensin RsAFP2 (solid lines) at concentrations of 25 g/ml (triangles), 50
g/ml (squares), or 100 g/ml (circles) for 24 h at 37°C in RPMI medium.
After 24 h of biofilm formation, biofilms were quantified with the CTB assay.
Graph shows the percentage of fluorescence relative to the control treatment
(0.5% DMSO) and a representative of two independent biological experiments
that consisted of triplicate measurements.
TABLE 1 Activity of OSIP108 against biofilm formation of different
Candida strains
Strain OSIP108 BIC-2 (M)
C. albicans CAI4 4.5
C. albicans SC5314 5.3
C. albicans DAY286 7.0
C. albicans CAF2 9.0
C. albicans B2630 10.8
C. albicans B63195 10.8
C. glabrata BG2 100
C. dubliniensis NCPF 3949 100
C. krusei 100
TABLE 2 Activity of OSIP108 and analogues against biofilm formation
of C. albicans
OSIP108 or
analogue Peptide
BIC-2
(M)
Fold
change
OSIP108 MLCVLQGLRE 5.3
S-OSIP108 ELRLVCMGQL 100 20
D-OSIP108 MLCVLQGLRE (all D-amino acids) 13.7 2.6
[CYC1]OSIP108 Cyclo-MLCVLQGLRE 100 20
[CYC2]OSIP108 Cyclo-MLCVLQGLREGG 36.0 6.8
[CYC3]OSIP108 Cyclo-MLCVLQGLREC 100 20
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spectrum antibiofilm agent, it remains a valuable peptide in tack-
ling biofilm-associated infections caused by C. albicans, the pre-
dominant fungal pathogen in humans (3, 4).
The use of (antimicrobial) peptides from various natural
sources as new antibiofilm agents as alternatives to antibiotics/
antimycotics has been increasingly studied during the last few
years. For example, antibiofilm activity was reported for LL-37
(the major human cationic host defense peptide) against several
Gram-negative and Gram-positive bacteria (38, 39), as well as
against C. albicans, where it interferes with adhesion (40, 41).
Moreover, the antibiofilm activity against C. albicans of synthetic
antimicrobial peptides such as KSL-W and KABT-AMP has been
reported (42, 43). In contrast to OSIP108, these synthetic peptides
do not act in a biofilm-specific way, as they display rather general
fungicidal activity.
Structure-activity relationship study of OSIP108. We
undertook a preliminary structure-activity relationship (SAR)
study of OSIP108 to identify elements of the structure important
for its antibiofilm activity. A scrambled version of OSIP108 (S-
OSIP108), containing the same amino acids as OSIP108 but in a
random order, was tested (Table 2) but displayed no antibiofilm
activity (BIC-2, 100 M), pointing to the importance of the
order of the amino acids for the antibiofilm activity of OSIP108.
Moreover, a D-stereoisomer of OSIP108, in which all the amino
acids are in the D-configuration (D-OSIP108), was synthesized and
tested to assess the role of stereochemistry on the activity (Table
2). The D-OSIP108 was confirmed by CD spectroscopy to have
equal and opposite mean residue ellipticity ([]MR) and thereby
mirror image symmetry to its OSIP108 enantiomer (see Fig. S2 in
the supplemental material). The optical isomerization was further
demonstrated in the CD spectrum of a 50:50 mixture of
L-OSIP108 and D-OSIP108, which counterbalanced each other
and showed a signal close to zero (see Fig. S2). Interestingly, the
BIC-2 of D-OSIP108 (13.7M) was only 2.6-fold higher than that
of the native OSIP108 peptide (5.3 M). If OSIP108 acts exclu-
sively via a stereospecific receptor, a more pronounced increase in
BIC-2 (i.e., a greater loss of activity) would have been expected,
while if it acts exclusively via a nonchiral mechanism (e.g., via
membrane lipid disruption), a minimal change in activity would
have been expected. The observed BIC-2 suggests that OSIP108
might have several alternative mechanisms contributing to its
mode of action. Moreover, the fact that D-OSP108 retains antib-
iofilm activity is beneficial in terms of possible applications of
OSIP108 as antibiofilm therapy, as peptides in the D-configura-
tion are less sensitive to endogenous proteases (44).
We subsequently examined the role of conformational restriction
on the activity of OSIP108. As cyclization is a well-established way to
stabilize peptides for therapeutic applications (45), we synthesized
three cyclic derivatives using either head-to-tail or disulfide-based
cyclization. The antibiofilm properties of the cyclic derivatives of
OSIP108 ([CYC1]OSIP108, [CYC2]OSIP108, and [CYC3]OSIP108)
were tested (Table 2). [CYC1]OSIP108 has the same sequence as the
native OSIP108, except that the N and C termini are joined head-to-
tail to cyclize the peptide. Cyclization of the [CYC2]OSIP108 peptide
was similarly performed, but two glycine residues were added to alter
the steric restraints associated with head-to-tail cyclization of the pep-
tide. In the [CYC3]OSIP108 peptide, an extra cysteine residue was
added to form a disulfide bridge with the cysteine at position 3
(Cys3), to form a disulfide-cyclized peptide. For [CYC1]OSIP108 and
[CYC3]OSIP108, the antibiofilm activity was totally abolished
(BIC-2, 100 M). For [CYC2]OSIP108, the BIC-2 (36 M) was
increased 6.8-fold compared to that of the native OSIP108 peptide
(BIC-2, 5.3M). These data demonstrate that cyclization reduces the
antibiofilm activity of OSIP108.
As well as being cyclic, the [CYC3]OSIP108 analogue seques-
ters the native Cys3 side chain in a disulfide bond, rather than as a
free thiol, and this could be a factor in reducing its activity. Fur-
thermore, we considered the possibility that this Cys might be
involved in the formation of a disulfide-linked dimer in OSIP108
but found no evidence of such a dimer in any of the chromato-
graphic or mass spectrometry data (data not shown).
OSIP108 does not affect viability or functionality of osteo-
blasts, mesenchymal stromal cells, or endothelial cells. As an
application of OSIP108 could imply its coating on medical de-
vices, we assessed the viability and functionality of various human
cell types such as osteoblasts, mesenchymal stromal cells, and en-
dothelial cells in the presence of OSIP108. OSIP108 (12.5M) did
not significantly decrease viability of osteoblasts, mesenchymal
stromal cells, and endothelial cells compared to the DMSO con-
trol (data not shown). Phenol (0.05%) was used as a positive con-
trol and significantly affected the viabilities of all cell types. In
addition, OSIP108 (12.5 M) had no significant effect (P 0.05)
on the osteogenic potential of osteoblasts compared to the DMSO
control treatment, as measured by calcium deposition (data not
shown). OSIP108 (12.5 M) significantly affected the osteogenic
potential of mesenchymal stromal cells compared to the DMSO
control treatment (0.161 
 0.003 ng Ca/g DNA for OSIP108-
treated cells versus 0.167
 0.0045 ng Ca/g DNA for the DMSO
control treatment). However, as this difference is very small and
no significant difference in calcium deposition between the
OSIP108-treated sample and the mesenchymal stromal cells cul-
tured in osteogenic medium (without DMSO) (0.162 ng
 0.006
Ca/g DNA) was observed, we can conclude that there is no sig-
nificant negative effect of OSIP108 on the osteogenic potential of
this cell type. Furthermore, OSIP108 did not reduce the potential
of endothelial cells to form tubular structures (Fig. 2). No signif-
icant differences in average tube length of endothelial cells were
observed in the presence of 12.5M OSIP108 (126
 18 pixels for
OSIP108-treated endothelial cells compared to 117
 5 pixels for
the DMSO control treatment), in contrast to 0.05% phenol, which
significantly (P  0.05) affected the average tube length (87 
 8
pixels).
OSIP108 enhances the activity of amphotericin B and caspo-
fungin in vitro and in vivo in aC. albicansworm infection assay.
As OSIP108 is not antifungal or fungicidal, and hence has a differ-
ent mode of antibiofilm action than conventional antifungal
agents like AMB and CAS, we investigated a potential synergy
between OSIP108 and AMB or CAS against mature C. albicans
biofilms using checkerboard analysis. OSIP108 (12.5 to 100 M)
significantly reduced the BEC-2 of AMB and CAS against mature
C. albicans biofilms (P  0.05). Moreover, in this concentration
range (12.5 to 100 M), OSIP108 acted synergistically with AMB
and CAS against mature C. albicans biofilms, as indicated by their
corresponding FICI coefficients being 0.5. The highest reduc-
tions in the BEC-2 values of AMB and CAS were observed in
combination with 100 M OSIP108, resulting in 4- to 5-fold re-
ductions of the BEC-2 values of AMB and CAS (from 0.72 M to
0.17 M for AMB and from 0.52 M to 0.11 M for CAS). FICI
coefficients for these OSIP108-AMB and OSIP108-CAS interac-
tions were0.36 and0.33, respectively.
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To translate the in vitro findings regarding the OSIP108 antib-
iofilm activity to an in vivo infection model, we used the Caeno-
rhabditis elegans-C. albicans infection assay, which is regarded as a
good infection model for studying biofilm-associated infections
(35, 46–50). Application of OSIP108 (25 to 100M) alone did not
significantly cure C. elegans worms infected with C. albicans com-
pared to the control treatment (data not shown). We further in-
vestigated the in vivo synergy with different types of antifungal
agents using the OSIP108-CAS combination. Treatment of the
infected worms with a combination of 100M OSIP108 and 0.095
M CAS significantly (P  0.05) increased the survival of the
worms compared to treatment with 100 M OSIP108 or 0.095
M CAS alone or control treatment (0.6% DMSO) after 3, 5, and
7 days postinfection (Fig. 3). Seven days postinfection, 42.78%

4.07% of the worms survived when treated with the combination
of OSIP108 and CAS. In contrast, treatment with CAS or OSIP108
alone resulted in only 19.15%
 3.21% or 2.81%
 0.57% surviv-
ing worms, respectively, whereas 5.45% 
 0.57% of the worms
treated with 0.6% DMSO (control treatment) survived 7 days
postinfection (Fig. 3). These data indicate that OSIP108 also en-
hances the activity of CAS in vivo in the C. elegans infection model
and suggest that OSIP108 might be a valuable adjuvant for con-
ventional antifungal agents like AMB and CAS in systemic com-
bination therapy against C. albicans biofilm-associated infections.
Further studies using appropriate models (e.g., a well-established
in vivo biofilm-associated rat catheter model [51]) are required to
confirm this synergy. Although the primary application of
OSIP108 could be envisaged in systemic combination therapy,
another potential application concerns its use as a coating of spe-
cific medical devices, such as dental implants, dentures, and voice
prostheses, as C. albicans is the most prevalent fungus in the oral
cavity (52) and is the most frequently isolated Candida spp. on
voice prostheses in laryngectomized patients (53). Regarding to
the latter, infection risk of these voice prostheses is very high (50 to
100%) compared to the risk with other implantable biomaterials
(13). We reason that biofilms growing on OSIP108-coated medi-
cal devices such as voice prostheses might be more easily eradi-
cated by conventional antifungal agents. In this regard, it is of
great importance that the OSIP108-containing coatings are not
cytotoxic for the surrounding tissue. As described above, OSIP108
had no cytotoxic effects on various human cell lines.
C. albicans mutants defective in components important for
cell wall integrity or hyphalmorphogenesis show increased tol-
erance toOSIP108. Important steps in the biofilm formation pro-
FIG 2 OSIP108 does not affect average tube length formed by endothelial cells. Human aortic endothelial cells were cultured in M200 medium with low serum
growth supplement (ENDO) in the presence of 12.5 M OSIP108, 0.5% DMSO (control treatment), or 0.05% phenol (positive control). Eight hours after
seeding, digital images for each treatment were taken.
FIG 3 OSIP108 enhances the activity of caspofungin in a C. elegans-C. albicans biofilm infection model. glp4/sek1 C. elegans worms were infected with C.
albicans by feeding them on a YPD plate containing C. albicans for 2 h at 25°C. Worms were subsequently treated with 100 M OSIP108 (open triangles), 0.095
M CAS (filled squares), or 100 M OSIP108	 0.095 M CAS (filled triangles). Untreated worms (filled circles) and noninfected worms (solid line) served as
controls with a DMSO background of 0.6%. Worms were counted regularly for 7 days postinfection. Worm survival is expressed as a percentage of their viability
at day 0. Data presented are the mean and SEM for one representative experiment out of three independent biological experiments, each consisting of at least
three repeats/condition. NI, noninfected worms; **, P 0.01.
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cess of C. albicans include the adhesion of cells to various surfaces
via cell wall proteins and the yeast-to-hypha transition (54). Fur-
thermore, the importance of the yeast-to-hypha transition and the
presence of both morphological forms for proper C. albicans bio-
film formation and structure were demonstrated by Baillie and
Douglas (55). In a first attempt to obtain more insight into the
antibiofilm mode of action of OSIP108 against C. albicans biofilm
formation, we screened a set of homozygous C. albicans deletion
mutants, affected in genes encoding cell wall proteins or transcrip-
tion factors involved in hyphal morphogenesis, for altered sensi-
tivity to OSIP108 during biofilm formation. We identified 9 mu-
tants that displayed at least a 5-fold increased tolerance and 1
mutant that displayed a 5-fold increased sensitivity to the antib-
iofilm activity of OSIP108. Targeted genes of these mutants were
divided in two main functional groups, genes encoding proteins
that are important to maintain cell wall integrity (CWI) and struc-
ture and genes encoding proteins involved in hyphal morphogen-
esis.
The first group of OSIP108-tolerant mutants was affected in
genes encoding proteins that function in cell wall integrity (CWI)
or cell wall structure (WSC1, SAP10, and CMP1). For example,
Wsc1 is the orthologue of S. cerevisiae Wsc2/Wsc3, sensor-trans-
ducer of the CWI pathway (56–58), and SAP10 encodes the se-
creted aspartyl protease 10, which is important in adhesion, viru-
lence, and cell surface integrity in C. albicans (59). CMP1 encodes
the catalytic subunit of calcineurin and is required for virulence
and tolerance to several stresses (60, 61). The second group of
mutants consisted of 2 mutants with a homozygous deletion of
transcription factors involved in hyphal morphogenesis, namely,
Cph2 and Tec1 (62, 63), and 2 mutants affected in hypha-specific
genes (HWP1, RAX2). The tec1 deletion mutant was the only
mutant characterized by an increased sensitivity to OSIP108. In
addition, three homozygous deletion mutants (orf19.2476,
pga45, and sod6) not directly related to these two functional
groups were identified as tolerant to the antibiofilm activity of
OSIP108. Based on these results taken together, we can conclude
that mutants defective in components important for CWI or hy-
phal morphogenesis showed increased tolerance to OSIP108.
OSIP108 dominantly localizes to the surface of C. albicans
cells. Based on our findings of a possible cell wall-related interac-
tion of OSIP108, we further investigated its localization using an
FITC-labeled OSIP108 peptide. We found FITC-OSIP108 (50
M) to be dominantly associated with the cell surface of C. albi-
cans (Fig. 4). The addition of the FITC group to the N-terminal
side of OSIP108 did not alter the antibiofilm activity compared
with that of the native OSIP108 peptide (data not shown). From
these data, it seems that OSIP108 exerts its antibiofilm effect by
associating with the C. albicans cell surface.
OSIP108 activates the cell wall integrity pathway of C. albi-
cans via Mkc1p activation. As the deletion mutant of the sensor-
transducer of the C. albicans CWI pathway (wsc1) and deletion
mutants of other genes important for cell surface integrity
(sap10 and cmp1) showed increased tolerance to OSIP108, we
investigated a potential activation of the CWI pathway by
OSIP108 (Fig. 5). The C. albicans CWI pathway contains the mi-
togen-activated protein (MAP) kinase Mkc1p, which is dually
phosphorylated upon activation of this pathway (36). We ob-
served a 2.7-fold increase in dually phosphorylated Mkc1p, in re-
sponse to OSIP108 compared to the control treatment (0.5%
DMSO), pointing to an activation of the CWI pathway by
OSIP108. Together with the above-described FITC localization
data, these data demonstrate that cell wall-related processes seem
important for the antibiofilm activity of OSIP108.
The yeast-to-hypha inhibitor RsAFP2 blocks the antibiofilm
activity of OSIP108. As some deletion mutants targeted in tran-
scription factors related to hyphal morphogenesis showed an
altered susceptibility toward OSIP108 (cph2 and tec1), we
first investigated a potential effect of OSIP108 on the yeast-to-
hypha transition of C. albicans. To this end, we determined the
percentage of hyphal mass in the presence of OSIP108 or the non-
FIG 4 Localization of FITC-labeled OSIP108 on C. albicans biofilm cells. C.
albicans biofilms were grown for 24 h in the presence of 50M FITC-OSIP108.
Biofilm cells were collected, and the localization of FITC-OSIP108 was visual-
ized using a fluorescence microscope (63 magnification). Scale bar repre-
sents 20 M.
FIG 5 OSIP108 activates the cell wall integrity pathway of C. albicans. WT
(SC5314) C. albicans cells growing in RPMI at 25°C were treated for 1 h with
100M OSIP108 (	) or 0.5% DMSO () as control treatment. Total protein
was extracted, and equal amounts of protein were loaded in each lane of an
SDS-PAGE gel and Western blotted to detect dually phosphorylated Mkc1p
(top) or actin (bottom). Numbers at the bottom indicate amount of dually
phosphorylated Mkc1p normalized to actin levels and shown relative to the
DMSO control. Blot presented is a representative blot out of three biological
experiments.
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active S-OSIP108 relative to the control treatment (0.5% DMSO).
No significant differences in hyphal mass were observed between
OSIP108, S-OSIP108, and DMSO treatments, indicating that
OSIP108 does not interfere with the yeast-to-hypha transition of
C. albicans (data not shown). Next, we investigated the effect of
the plant defensin RsAFP2, which reportedly blocks the yeast-to-
hypha transition in C. albicans (64), on the antibiofilm activity of
OSIP108 (Fig. 1). Coincubation of OSIP108 with 25 g/ml
RsAFP2 increased the BIC-2 of OSIP108 from 5 M to 19 M.
Moreover, coincubation of OSIP108 with 50 and 100 g/ml
RsAFP2 totally abolished its antibiofilm activity (BIC-2, 100
M). Likewise, another synthetic yeast-to-hypha inhibitor, con-
jugated linoleic acid (CLA) (65), had an antagonistic effect on the
antibiofilm activity of OSIP108. Although coincubation of 100
M CLA with a concentration series of OSIP108 did not change
the BIC-2 value of OSIP108, a 7-fold increase in the OSIP108
concentration necessary to reduce biofilm formation by 80% was
observed in the presence of 100 M CLA (data not shown). It is
important to note that RsAFP2, besides its action on the yeast-to-
hypha transition of C. albicans, also induces cell wall stress, septin
mislocalization, and accumulation of ceramides in C. albicans
(64). Hence, it cannot be ruled out that the antagonistic activity of
RsAFP2 on the antibiofilm activity of OSIP108, is not solely due to
its effect on the yeast-to-hypha transition. However, the fact that
another yeast-to-hypha inhibitor, CLA, also antagonizes the anti-
biofilm activity of OSIP108 points to the importance of this mor-
phological transition switch of C. albicans for OSIP108 antibio-
film activity. In line with these findings, fungal pathogens that do
not form true hyphae in their biofilms, like C. glabrata and C.
krusei (66, 67), were resistant to OSIP108. However, C. dublinien-
sis, which is closely related to C. albicans and forms true hyphae in
biofilms (68), was also resistant to OSIP108.
Conclusions. In this study, we found that the plant-derived
decapeptide OSIP108 interferes with the biofilm formation pro-
cess of the human fungal pathogen C. albicans. This antibiofilm
activity is biofilm specific, as OSIP108 does not affect the growth
and viability of planktonic C. albicans cultures. Using in vitro
checkerboard analysis and an in vivo C. elegans-C. albicans biofilm
infection model, we showed that OSIP108 synergistically en-
hances the activity of conventional antifungal agents such as AMB
and CAS, pointing to a potential application of OSIP108 in sys-
temic combination therapies. Since OSIP108 shows no toxicity
against several cell types, like osteoblasts, mesenchymal stem cells,
and endothelial cells, OSIP108 might be an interesting peptide to
coat specific medical devices, like voice prostheses, as C. albicans
biofilm formation is a significant clinical problem associated with
this medical device. Initial steps in the elucidation of the mode of
action revealed the importance of the yeast-to-hypha transition of
C. albicans for OSIP108’s antibiofilm activity, as well as of cell
wall-associated processes, as indicated by OSIP108’s dominant
localization to the C. albicans cell surface and the activation of its
cell wall integrity pathway.
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